CLVL.F Stock Overview
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Clinuvel Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$9.82 |
52 Week High | AU$13.25 |
52 Week Low | AU$8.57 |
Beta | 0.74 |
1 Month Change | 11.85% |
3 Month Change | n/a |
1 Year Change | -24.69% |
3 Year Change | -57.67% |
5 Year Change | -42.48% |
Change since IPO | 4,363.64% |
Recent News & Updates
Recent updates
Shareholder Returns
CLVL.F | US Biotechs | US Market | |
---|---|---|---|
7D | 3.3% | 1.0% | 1.2% |
1Y | -24.7% | 0.7% | 24.9% |
Return vs Industry: CLVL.F underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: CLVL.F underperformed the US Market which returned 24.7% over the past year.
Price Volatility
CLVL.F volatility | |
---|---|
CLVL.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLVL.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CLVL.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | Philippe Wolgen | www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Limited Fundamentals Summary
CLVL.F fundamental statistics | |
---|---|
Market cap | US$488.31m |
Earnings (TTM) | US$19.60m |
Revenue (TTM) | US$53.15m |
24.9x
P/E Ratio9.2x
P/S RatioIs CLVL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLVL.F income statement (TTM) | |
---|---|
Revenue | AU$81.76m |
Cost of Revenue | AU$6.70m |
Gross Profit | AU$75.06m |
Other Expenses | AU$44.90m |
Earnings | AU$30.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.60 |
Gross Margin | 91.80% |
Net Profit Margin | 36.88% |
Debt/Equity Ratio | 0% |
How did CLVL.F perform over the long term?
See historical performance and comparison